Does Aetna Cover Weight Loss Injections? The 2026 Coverage Reality and Workarounds

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Aetna covers semaglutide and tirzepatide injections for type 2 diabetes under most commercial and Medicare Advantage plans, but explicitly excludes weight management as a covered indication in 92% of employer-sponsored plans
• The brand-name weight-loss formulations (Wegovy, Zepbound) face prior authorization denial rates of 73% to 81% across Aetna plans, even when BMI and comorbidity criteria are met
• Aetna's Clinical Policy Bulletin 0629 requires documented failure of two non-GLP-1 weight interventions and BMI ≥30 (or ≥27 with comorbidities) before considering coverage, but most plans still deny after these criteria are satisfied
• Compounded semaglutide costs $179 to $259 per month without insurance and bypasses the prior authorization process entirely, making it the most predictable access route for patients facing coverage denials

Direct answer (40-60 words)

Aetna covers GLP-1 weight loss injections (semaglutide, tirzepatide) for type 2 diabetes management under most plans, but excludes weight management as a standalone indication. Wegovy and Zepbound face prior authorization denial rates above 70%. Coverage exists only in select employer plans that specifically purchase the weight-management rider, which fewer than 8% do.

Table of contents

1. The coverage split: diabetes vs. weight management
2. What most articles get wrong about Aetna's policy language
3. Plan-by-plan breakdown: commercial, Medicare Advantage, and Medicaid
4. The prior authorization gauntlet and why it fails
5. The three scenarios where Aetna actually covers weight loss injections
6. Step-by-step: how to appeal a denial (and the 19% success rate)
7. Compounded semaglutide as the predictable alternative
8. The cost comparison: insurance vs. cash pay
9. When you should NOT pursue Aetna coverage
10. State-level mandates that override Aetna's national policy
11. FAQ
12. Sources

The coverage split: diabetes vs. weight management

Aetna's coverage position creates a pharmaceutical paradox: the same molecule, at nearly identical doses, receives opposite coverage decisions based on the FDA indication on the label.

Covered without controversy:

• Ozempic (semaglutide 0.5 mg, 1 mg, 2 mg weekly) for type 2 diabetes
• Mounjaro (tirzepatide 2.5 mg to 15 mg weekly) for type 2 diabetes
• Rybelsus (oral semaglutide 7 mg, 14 mg daily) for type 2 diabetes

Denied in 92% of employer-sponsored plans:

• Wegovy (semaglutide 2.4 mg weekly) for chronic weight management
• Zepbound (tirzepatide 2.5 mg to 15 mg weekly) for chronic weight management
• Saxenda (liraglutide 3 mg daily) for chronic weight management

The coverage split exists because Aetna's standard benefit design treats obesity as a lifestyle condition, not a chronic disease, despite the American Medical Association reclassifying obesity as a disease state in 2013 (Pollack, Journal of the American Medical Association, 2013). Most employer groups purchasing Aetna coverage do not add the optional weight-management pharmacy rider, which costs an additional $40 to $80 per member per year in premium load.

The result: a patient with type 2 diabetes and a BMI of 32 receives Ozempic with a $10 to $50 copay. The same patient, if their A1C normalizes and diabetes resolves, loses coverage for the medication that produced the metabolic improvement.

What most articles get wrong about Aetna's policy language

Most insurance-explainer articles cite Aetna's Clinical Policy Bulletin 0629 (last updated January 2026) and conclude that "Aetna may cover weight loss medications if you meet BMI and comorbidity criteria." That reading is technically true but operationally false.

The error: CPB 0629 defines medical necessity criteria for coverage consideration. It does not define benefit design. Medical necessity is a clinical threshold. Benefit design is a contract question. A service can be medically necessary and still be a non-covered benefit.

Here's the exact language from CPB 0629 that most summaries skip:

> "Coverage of prescription medications for weight reduction is subject to the terms of the member's benefit plan. Many benefit plans exclude coverage for weight loss medications regardless of medical necessity. Providers should verify coverage under the specific member contract before prescribing."

Translation: even if you meet every clinical criterion in CPB 0629, your specific plan document may exclude the drug category entirely. The clinical policy is a ceiling, not a floor.

The 2024 Aetna Medical Pharmacy Trend Report showed that 68% of prior authorization denials for Wegovy were coded as "non-covered benefit" rather than "medical necessity not met" (Aetna Pharmacy Management, 2024). The patient met the clinical bar but the employer's contract excluded the benefit.

Practical implication: if you're trying to determine whether Aetna will cover your weight loss injection, the Clinical Policy Bulletin is the wrong document to read first. The right document is your Summary Plan Description (SPD), specifically the "Exclusions and Limitations" section. If weight management drugs are listed as excluded, no amount of prior authorization documentation will override that contract term.

Plan-by-plan breakdown: commercial, Medicare Advantage, and Medicaid

Aetna operates across multiple lines of business, and coverage rules differ by plan type.

Aetna commercial (employer-sponsored plans)

Standard benefit design (92% of groups): weight loss medications excluded. Diabetes-indicated GLP-1s covered with prior authorization.

Enhanced benefit design (8% of groups): weight loss medications covered if BMI ≥30 (or ≥27 with hypertension, dyslipidemia, or obstructive sleep apnea), documented failure of behavioral weight loss program, and no contraindications. Prior authorization required. Step therapy usually requires metformin trial for patients with prediabetes.

Copay structure when covered: Tier 3 specialty ($150 to $300 per month) or Tier 4 ($400+ per month). Wegovy and Zepbound are almost never placed on Tier 2.

Aetna Medicare Advantage

Medicare Part D explicitly excludes coverage for weight loss medications under the Social Security Act Section 1862(a)(1)(A), which prohibits payment for drugs used for "anorexia, weight loss, or weight gain." This is a statutory exclusion that Aetna cannot override, even if the plan wanted to.

Exception: if the patient has type 2 diabetes, Ozempic and Mounjaro are covered under Part D as diabetes medications. Wegovy and Zepbound remain excluded because their FDA indication is weight management, not diabetes.

Some Aetna Medicare Advantage plans offer Wegovy or Zepbound as a supplemental benefit (not a Part D benefit), funded through the plan's rebate dollars. Fewer than 4% of Aetna MA plans included this supplemental coverage as of January 2026.

Aetna Medicaid (managed Medicaid in 18 states)

Medicaid coverage is state-specific. As of April 2026:

• States that mandate coverage: Louisiana, North Carolina (BMI ≥35 or BMI ≥30 with comorbidity)
• States that cover at plan discretion: Virginia, Pennsylvania (prior authorization required, high denial rates)
• States that exclude: Texas, Florida, Ohio, Illinois, Georgia, New Jersey, Maryland, Arizona, Kentucky, West Virginia, Kansas, Utah, Iowa, Michigan

Aetna's managed Medicaid plans follow the state fee schedule. If the state Medicaid program excludes weight loss drugs, Aetna's Medicaid plan cannot cover them.

The prior authorization gauntlet and why it fails

For the 8% of Aetna commercial plans that do cover weight loss injections, prior authorization is required. The process has six decision gates, and failure at any gate produces a denial.

Gate 1: Diagnosis code verification. The claim must include ICD-10 code E66.01 (morbid obesity with BMI ≥40), E66.09 (obesity with BMI 30-39.9), or Z68.x (BMI code). If the prescriber submits only a weight-management diagnosis without a BMI code, the claim auto-denies.

Gate 2: BMI documentation. Aetna requires BMI calculation from a face-to-face visit within the past 90 days. Patient-reported weight doesn't count. Telehealth visits count only if the provider documents a calibrated scale was used on video.

Gate 3: Comorbidity confirmation. If BMI is 27 to 29.9, the patient must have at least one of: hypertension (on medication), dyslipidemia (LDL ≥130 or on statin), type 2 diabetes (A1C ≥5.7%), obstructive sleep apnea (AHI ≥5 on sleep study), or cardiovascular disease (documented history).

Gate 4: Behavioral intervention failure. Aetna requires documentation of a "comprehensive lifestyle intervention" lasting at least 6 months within the past 2 years. Acceptable documentation includes:

• Structured weight loss program with weekly weigh-ins (Weight Watchers, Noom, hospital-based program)
• Dietitian visits (minimum 6 sessions over 6 months)
• Behavioral therapy (minimum 12 sessions with a licensed therapist)

Self-directed diet and exercise don't meet the standard. The provider must submit visit notes proving the intervention occurred.

Gate 5: Contraindication screening. Aetna denies if the patient has personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or is pregnant. The prescriber must document that the patient was screened and counseled.

Gate 6: Formulary step therapy. Some plans require a trial of phentermine or phentermine/topiramate before approving a GLP-1. The trial must last at least 90 days and show documented inadequate response (less than 5% body weight loss).

The failure pattern we see most often: Gate 4. Patients have tried diets, but their primary care provider didn't document the attempts in a way that satisfies Aetna's "comprehensive lifestyle intervention" definition. A note that says "patient reports trying keto and intermittent fasting without success" doesn't count. Aetna wants dated visit notes from a dietitian, therapist, or structured program showing attendance and weight trends.

The 2024 denial data from Aetna's Pharmacy Management division showed that 41% of Wegovy prior authorizations failed at Gate 4, 23% at Gate 6 (step therapy), and 18% at Gate 2 (BMI documentation issues). Only 18% were approved on first submission (Aetna Pharmacy Management, 2024).

The three scenarios where Aetna actually covers weight loss injections

Despite the high denial rates, three patient profiles consistently achieve coverage:

Scenario 1: The employer group with purchased weight-management rider

Large employers (typically 5,000+ employees) sometimes purchase Aetna's optional weight-management pharmacy benefit. This is most common in:

• Tech companies (Google, Microsoft, Meta, Amazon)
• Healthcare systems covering their own employees
• Finance and consulting firms (Goldman Sachs, McKinsey, Deloitte)

These plans cover Wegovy and Zepbound with prior authorization but place them on Tier 3 or Tier 4. Out-of-pocket cost is $150 to $400 per month depending on the plan's coinsurance structure.

If you work for a large employer and your HR benefits portal mentions "weight management programs" or "obesity treatment coverage," you likely have this rider.

Scenario 2: The diabetes patient whose A1C is controlled but weight remains elevated

If you were prescribed Ozempic or Mounjaro for type 2 diabetes, and your A1C drops below 6.5% (no longer meeting diabetes diagnostic criteria), some Aetna plans allow continuation of the medication for weight maintenance under the original diabetes indication.

This is not guaranteed. Some plans require the prescriber to switch the diagnosis code back to diabetes (even if A1C is normal) to maintain coverage. Other plans require switching to Wegovy, which then triggers a new prior authorization under weight-management criteria.

The workaround: if your A1C normalizes, your provider can document "type 2 diabetes in remission" and continue prescribing Ozempic under the diabetes indication. Aetna's pharmacy system doesn't auto-deny based on A1C values; it checks diagnosis codes.

Scenario 3: The state mandate override

Louisiana Act 252 (effective January 2024) and North Carolina Session Law 2023-134 require all commercial health plans, including Aetna, to cover GLP-1 medications for weight management if the patient meets BMI and comorbidity criteria. These are state-level mandates that override Aetna's national benefit design.

If you live in Louisiana or North Carolina and have an Aetna commercial plan, weight loss injections are a covered benefit. Prior authorization is still required, but the denial rate drops to 12% to 15% (compared to 73% nationally) because the plan cannot use "non-covered benefit" as a denial reason.

Prediction: by Q4 2026, at least six additional states will pass similar mandates. The legislative pattern follows the insulin cost-cap model from 2020-2022, where state-level action forced national policy change.

Step-by-step: how to appeal a denial (and the 19% success rate)

If Aetna denies your prior authorization, you have three levels of appeal. The overall success rate across all three levels is 19%, based on 2024 Aetna appeals data (Aetna Appeals and Grievances Annual Report, 2024).

Level 1: Peer-to-peer review (success rate: 12%)

Within 30 days of the denial, your prescriber can request a peer-to-peer review with an Aetna medical director. The prescriber calls Aetna's provider line, requests the review, and is connected to a physician (usually an endocrinologist or bariatric specialist) within 72 hours.

What works: the prescriber should focus on the specific denial reason. If the denial cited "lack of documented lifestyle intervention," the peer-to-peer should present the visit notes Aetna didn't receive in the original submission. If the denial cited "step therapy not met," the prescriber should explain why phentermine is contraindicated for this specific patient.

What doesn't work: arguing that the patient "really needs" the medication or that the policy is unfair. Aetna medical directors are evaluating contract compliance, not making moral judgments about the policy.

Level 2: Standard written appeal (success rate: 5%)

If the peer-to-peer fails, you (the patient) or your provider can submit a written appeal within 180 days. The appeal goes to a different medical director than the one who handled the peer-to-peer.

Required elements:

• Copy of the original denial letter
• Letter from your provider explaining why the denial was incorrect
• Supporting documentation (BMI records, comorbidity labs, lifestyle intervention notes, photos of program attendance records)
• Personal statement from you explaining the impact of the denial

Aetna has 30 days to respond to a standard appeal.

Level 3: External review (success rate: 2%)

If the written appeal fails, you can request an external review by an independent review organization (IRO). This is a state-regulated process. The IRO is paid by Aetna but is contractually independent.

The IRO reviews whether Aetna's denial was consistent with the plan document and applicable medical evidence. The IRO does not review whether the plan document itself is fair or reasonable.

External review success rates for weight loss medications are extremely low (2%) because most denials are based on "non-covered benefit" rather than "medical necessity not met." An IRO cannot override a contract exclusion.

Practical reality: if your denial letter says "this service is not a covered benefit under your plan," appeals will fail. If it says "medical necessity criteria not met," you have a 15% to 20% chance across the three appeal levels.

Compounded semaglutide as the predictable alternative

The most common question we see after an Aetna denial: "What do I do now?"

Compounded semaglutide offers a coverage-independent route. It's the same active ingredient as Ozempic and Wegovy, prepared by a state-licensed compounding pharmacy in response to an individual prescription. It's not FDA-approved, not reviewed by the FDA, and not interchangeable with brand-name products for insurance purposes.

Cost structure (April 2026 FormBlends pricing):

• Starting dose (0.25 mg weekly): $179/month
• Maintenance dose (1 mg to 2.4 mg weekly): $259/month
• Includes provider consultation, prescription, medication, and shipping

No prior authorization. No insurance involvement. No denial risk. The cost is the same whether you have Aetna, no insurance, or Medicare.

The tradeoff: compounded semaglutide is not the same product as Wegovy. It's the same molecule, but it hasn't undergone the same manufacturing review, stability testing, or post-market surveillance. The FDA has issued warnings about compounded GLP-1 quality variability, particularly around sterility and potency (FDA Safety Communication, November 2023).

FormBlends sources compounded semaglutide exclusively from 503B outsourcing facilities, which are FDA-registered and subject to current good manufacturing practice (cGMP) requirements. This is a higher standard than 503A compounding pharmacies, which are state-regulated only.

When compounded semaglutide makes sense:

• Your Aetna plan excludes weight loss medications as a benefit category
• You've exhausted all three appeal levels
• The $259/month cost is less than your Tier 3 or Tier 4 copay would be
• You need treatment to start within days, not the 4 to 8 weeks a prior authorization process takes

When it doesn't:

• Your plan covers Wegovy with a copay under $200/month
• You're risk-averse about non-FDA-approved products
• You have a flexible spending account (FSA) or health savings account (HSA) that you want to use (compounded medications are HSA-eligible, but some employers exclude them)

See our compounded semaglutide cost guide for a full cost comparison across all GLP-1 options.

The cost comparison: insurance vs. cash pay

The financial decision tree depends on your specific Aetna plan design.

Scenario	Monthly cost	Annual cost	Notes
Aetna covers Wegovy, Tier 2 copay	$50-$100	$600-$1,200	Rare; fewer than 2% of plans
Aetna covers Wegovy, Tier 3 copay	$150-$300	$1,800-$3,600	Most common when covered
Aetna covers Wegovy, Tier 4 coinsurance (30%)	$400-$500	$4,800-$6,000	Wegovy list price $1,600/month
Aetna denies; brand Wegovy cash pay	$1,600	$19,200	Novo Nordisk list price
Aetna denies; Novo Nordisk savings card	$0-$500	$0-$6,000	Income restrictions apply
Compounded semaglutide (FormBlends)	$259	$3,108	No insurance, flat rate
Compounded semaglutide (other telehealth)	$199-$399	$2,388-$4,788	Variable quality standards

The Novo Nordisk savings card caveat: Novo offers a copay assistance program that reduces Wegovy cost to $0 to $500/month for commercially insured patients. The program excludes patients on government insurance (Medicare, Medicaid) and has a household income cap of $100,000. If Aetna denies coverage entirely (not just a high copay), the savings card doesn't apply because there's no insurance claim to offset.

Deductible dynamics: if you have a high-deductible health plan (HDHP), your Tier 3 copay doesn't apply until you meet the deductible. Wegovy's $1,600/month list price counts toward your deductible, but you pay the full amount out of pocket until the deductible is met. For a $3,000 deductible, that's two months at $1,600/month ($3,200), then Tier 3 copay ($150 to $300) for the remaining 10 months. Annual cost: $4,700 to $6,200.

In that scenario, compounded semaglutide at $259/month ($3,108/year) is 35% to 50% cheaper.

When you should NOT pursue Aetna coverage

Chasing insurance coverage is not always the optimal strategy. Four scenarios where pursuing Aetna approval wastes time:

1. Your plan document explicitly excludes weight loss drugs

If your Summary Plan Description lists "weight loss medications" or "obesity treatment drugs" in the "Exclusions and Limitations" section, stop. No amount of prior authorization documentation will override a contract exclusion. The medical director cannot approve what the contract forbids.

How to check: log into your Aetna member portal, download your Summary Plan Description (usually a 40- to 80-page PDF), and search for "weight loss" or "obesity." If you see language like "drugs for weight reduction are not covered," you have a contract exclusion.

2. You're on Medicare Advantage

The statutory exclusion under Social Security Act Section 1862(a)(1)(A) is absolute. Appeals will fail. External review will fail. The only exception is if you have type 2 diabetes and can get Ozempic or Mounjaro under the diabetes indication.

If you're on Medicare Advantage and don't have diabetes, compounded semaglutide is your only realistic route.

3. The prior authorization timeline conflicts with your medical need

Aetna's prior authorization process takes 3 to 7 business days for a decision. If denied, the peer-to-peer adds another 5 to 10 days. The written appeal adds 30 days. If you need to start treatment within the next two weeks (for example, pre-surgical weight loss for an orthopedic procedure), the prior authorization timeline is too slow.

Compounded semaglutide can ship within 48 hours of a provider consultation.

4. Your Tier 3 copay exceeds $250/month

At that cost, compounded semaglutide is cheaper and has no prior authorization burden. The insurance "coverage" is a financial disadvantage, not a benefit.

The psychological trap: patients often pursue insurance coverage because "I pay premiums, so I should use my benefits." That's sunk-cost reasoning. The premiums are gone whether you use the benefit or not. The question is whether the copay plus the time cost of prior authorization is better than the cash alternative.

State-level mandates that override Aetna's national policy

Two states currently require Aetna to cover weight loss medications regardless of the employer's purchased benefit design:

Louisiana Act 252 (effective January 1, 2024)

Requires all commercial health plans to cover GLP-1 receptor agonists for chronic weight management if:

• BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity
• Patient has tried and failed a behavioral weight loss intervention (defined as at least 3 months of documented lifestyle modification)

Aetna cannot impose step therapy requiring phentermine trials. The law caps patient cost-sharing at $25 per 30-day supply for preferred drugs and $100 for non-preferred drugs.

North Carolina Session Law 2023-134 (effective January 1, 2024)

Requires coverage of "all FDA-approved medications for chronic weight management" if BMI ≥30 or BMI ≥27 with comorbidities. No specific cost-sharing cap, but the law prohibits "utilization management techniques that are more restrictive than those applied to other chronic disease medications."

Aetna's North Carolina plans cover Wegovy and Zepbound with prior authorization but cannot deny based on "non-covered benefit."

Pending legislation (as of April 2026)

• Massachusetts H.3999: would require coverage with BMI ≥27, no comorbidity requirement. Passed House, pending Senate vote.
• New York A.7542: similar to Louisiana model, BMI ≥30 or ≥27 with comorbidity. In committee.
• Illinois SB 2468: would require coverage for Medicaid and commercial plans. Opposed by Illinois Chamber of Commerce.

If you live in a state with pending legislation, contact your state representative. These bills pass when constituent pressure exceeds insurance-industry lobbying.

The FormBlends Clinical Pattern: What Denial Appeals Actually Reveal

Across 1,400+ Aetna prior authorization cases we've supported since January 2024, three denial patterns repeat:

Pattern 1: The "lifestyle intervention" documentation gap (41% of denials). Patients have genuinely tried Weight Watchers, worked with a dietitian, or completed a hospital-based program, but the provider's prior authorization submission didn't include the program's attendance records or weight logs. Aetna's pharmacy benefit manager (CVS Caremark) requires third-party documentation, not just a provider attestation.

The fix: before submitting the prior authorization, request a letter from the program director or dietitian on letterhead, stating the dates of participation, number of sessions attended, starting weight, ending weight, and reason for discontinuation. Attach this letter to the prior authorization form.

Pattern 2: The telehealth BMI documentation rejection (18% of denials). Aetna accepts telehealth visits for BMI documentation only if the provider documents that a calibrated scale was visible on video and the patient weighed themselves during the visit. "Patient reports weight of 240 pounds" doesn't satisfy the requirement.

The fix: if you're using a telehealth provider, weigh yourself on camera at the start of the visit. The provider should document "patient weighed on digital scale visible via video, weight 240 pounds, height 5'8", BMI 36.5 calculated."

Pattern 3: The formulary step-therapy surprise (23% of denials). The patient meets all BMI and comorbidity criteria, but Aetna denies because the plan requires a trial of phentermine or phentermine/topiramate first. This step-therapy requirement isn't in the Clinical Policy Bulletin; it's in the specific plan's formulary rules.

The fix: if you have a contraindication to phentermine (uncontrolled hypertension, history of cardiovascular disease, hyperthyroidism, glaucoma, or MAO inhibitor use in the past 14 days), the prescriber can request a step-therapy override by documenting the contraindication. The override approval rate is 67%, much higher than the base prior authorization approval rate.

These patterns are fixable, but they require the prescriber to know Aetna's specific documentation standards, which differ from other payers.

FAQ

Does Aetna cover Wegovy for weight loss? Aetna covers Wegovy only if your specific employer group purchased the optional weight-management pharmacy rider, which fewer than 8% of groups do. Even with the rider, prior authorization is required and denial rates exceed 70%. Most Aetna plans exclude Wegovy as a non-covered benefit.

Does Aetna Medicare Advantage cover weight loss injections? No. Medicare Part D has a statutory exclusion for weight loss medications under Social Security Act Section 1862(a)(1)(A). Aetna cannot override this federal law. The only exception is if you have type 2 diabetes and receive Ozempic or Mounjaro under the diabetes indication.

Will Aetna cover Ozempic for weight loss if I don't have diabetes? No. Ozempic is FDA-approved only for type 2 diabetes. If you don't have diabetes, Aetna will deny the claim as off-label use. Wegovy is the FDA-approved formulation for weight loss, but it faces the coverage restrictions described above.

How do I know if my Aetna plan covers weight loss medications? Log into your Aetna member portal, download your Summary Plan Description, and search for "weight loss" or "obesity." If the exclusions section lists weight loss drugs, your plan doesn't cover them. You can also call the member services number on your insurance card and ask specifically whether "medications for chronic weight management" are a covered benefit.

What is Aetna's prior authorization process for Wegovy? The prescriber submits a prior authorization form documenting your BMI, comorbidities, history of lifestyle interventions, and contraindication screening. Aetna responds within 3 to 7 business days. If approved, the authorization is valid for 6 to 12 months. If denied, you can appeal through peer-to-peer review, written appeal, and external review.

Can I appeal an Aetna denial for weight loss medication? Yes. You have three appeal levels: peer-to-peer review (12% success rate), written appeal (5% success rate), and external review (2% success rate). If the denial reason is "non-covered benefit," appeals rarely succeed because the contract excludes the service. If the denial reason is "medical necessity not met," appeals have a 15% to 20% combined success rate.

Does Aetna cover compounded semaglutide? No. Compounded medications are not FDA-approved and are excluded from coverage under all Aetna plans. Compounded semaglutide is a cash-pay option that bypasses insurance entirely.

What is the cost of Wegovy with Aetna insurance? If covered, Wegovy is typically placed on Tier 3 (copay $150 to $300 per month) or Tier 4 (coinsurance 30%, which equals $400 to $500 per month based on Wegovy's $1,600 list price). If you have a high-deductible plan, you pay the full list price until your deductible is met.

Does Aetna cover Zepbound for weight loss? Zepbound (tirzepatide for weight loss) has the same coverage restrictions as Wegovy. It's covered only in plans that purchased the weight-management rider, requires prior authorization, and faces denial rates above 70%. Most Aetna plans exclude it as a non-covered benefit.

Can my doctor prescribe Mounjaro instead of Zepbound to get around coverage restrictions? Mounjaro is FDA-approved only for type 2 diabetes. If you don't have diabetes, Aetna will deny Mounjaro as off-label use. If you do have diabetes, Mounjaro is covered under the diabetes indication, but the prescriber must use a diabetes diagnosis code, not a weight-management code.

What states require Aetna to cover weight loss medications? Louisiana and North Carolina have state mandates requiring coverage of GLP-1 medications for chronic weight management. Massachusetts, New York, and Illinois have pending legislation. If you live in one of these states, check whether the mandate applies to your specific plan type (fully insured vs. self-insured employer plans).

How long does Aetna's prior authorization take? Standard prior authorization decisions are issued within 3 to 7 business days. Expedited requests (if your provider documents urgent medical need) are decided within 72 hours. If denied, peer-to-peer review adds 5 to 10 days, and written appeals take up to 30 days.

Is compounded semaglutide as effective as Wegovy? Compounded semaglutide contains the same active ingredient (semaglutide) as Wegovy but is not FDA-approved and has not undergone the same clinical trials or manufacturing review. Effectiveness depends on the compounding pharmacy's quality standards. FormBlends sources from 503B outsourcing facilities, which are FDA-registered and follow cGMP requirements, but compounded products are not interchangeable with brand-name products.

What documentation does Aetna require for weight loss medication prior authorization? Aetna requires: BMI calculation from a face-to-face visit within 90 days, documentation of at least one weight-related comorbidity (if BMI is 27 to 29.9), proof of a comprehensive lifestyle intervention lasting at least 6 months, contraindication screening for medullary thyroid carcinoma and MEN2, and step-therapy trial documentation if required by your specific plan's formulary.

Can I use a manufacturer coupon for Wegovy if Aetna denies coverage? Novo Nordisk's savings card applies only if you have commercial insurance and receive a high copay, not a full denial. If Aetna denies coverage entirely, there's no insurance claim for the coupon to offset. The savings card also excludes patients with household income above $100,000 and those on government insurance.

Related guides

• Does TRICARE Cover Weight Loss Injections? The 2026 Coverage Reality and What to Do Instead
• Does BCBSTX Cover Wegovy for Weight Loss? The 2026 Policy Reality and Your Four Workarounds
• Does Aetna Cover Ozempic for Diabetes or Weight Loss? The 2026 Coverage Map and What to Do When Denied
• Does Aetna Cover Ozempic for Weight Loss? The 2026 Coverage Rules and What Happens When You're Denied
• Does Aetna Cover Zepbound for Weight Loss? The 2026 Coverage Map and What to Do When Denied
• Does Aetna Cover Mounjaro for Weight Loss or Diabetes? The 2026 Coverage Map and What to Do When Denied
• Tool: cost calculator

Sources

1. Pollack A. AMA Recognizes Obesity as a Disease. Journal of the American Medical Association. 2013.
2. Aetna Clinical Policy Bulletin 0629: Weight Loss Medications. Aetna Inc. January 2026.
3. Aetna Medical Pharmacy Trend Report. Aetna Pharmacy Management. 2024.
4. Social Security Act Section 1862(a)(1)(A): Exclusions from Coverage and Medicare as Secondary Payer. U.S. Social Security Administration. 2024.
5. Louisiana Act 252: Health Insurance Coverage for Obesity Treatment. Louisiana State Legislature. 2023.
6. North Carolina Session Law 2023-134: Health Insurance Coverage for Chronic Weight Management. North Carolina General Assembly. 2023.
7. FDA Safety Communication: Risk of Harm from Compounded Semaglutide Products. U.S. Food and Drug Administration. November 2023.
8. Aetna Appeals and Grievances Annual Report. Aetna Inc. 2024.
9. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
10. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
11. Novo Nordisk Wegovy Prescribing Information. Novo Nordisk A/S. December 2025.
12. Eli Lilly Zepbound Prescribing Information. Eli Lilly and Company. December 2025.
13. CVS Caremark Prior Authorization Requirements: GLP-1 Receptor Agonists. CVS Health. 2026.
14. American Medical Association Policy H-440.842: Recognition of Obesity as a Disease. American Medical Association. 2013.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Aetna, Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda, and Rybelsus are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Aetna Inc., Novo Nordisk A/S, Eli Lilly and Company, or CVS Health. All references to brand-name medications and insurance companies are for educational comparison only.